Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Liangzhi, Xie"'
Autor:
Ruizhi Zhang, Junshi Zhao, Xiaoping Zhu, Qinghu Guan, Shujun Liu, Meihong Li, Jianghua Gao, Jie Tan, Feng Cao, Beifang Gan, Bo Wu, Jin Bai, Youquan Liu, Gang Xie, Chi Liu, Wei Zhao, Lixin Yan, Shuping Xu, Gui Qian, Dongfang Liu, Jian Li, Wei Li, Xuxin Tian, Jinling Wang, Shanshan Wang, Dongyang Li, Jing Li, Yuhuan Jiao, Xuefeng Li, Yuanxin Chen, Yang Wang, Wenlin Gai, Qiang Zhou, Liangzhi Xie
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Evolution of SARS-CoV-2 variants emphasizes the need for multivalent vaccines capable of simultaneously targeting multiple strains. SCTV01E is a tetravalent COVID-19 vaccine derived from the spike protein of SARS-CoV-2 variants Alpha, Beta,
Externí odkaz:
https://doaj.org/article/9b8d8c31580844d5b126ead3660a8fc0
Autor:
Ming Bai, Yao Lu, Chunmei Shi, Jianwei Yang, Wei Li, Xianli Yin, Chenghui Huang, Lin Shen, Liangzhi Xie, Yi Ba
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 7, Pp 636-650 (2024)
Objective: This study evaluated the safety and efficacy of an anti-epidermal growth factor receptor (EGFR) antibody (SCT200) and an anti-programmed cell death 1 (PD-1) antibody (SCT-I10A) as third-line or subsequent therapies in patients with rat sar
Externí odkaz:
https://doaj.org/article/94a160b89a9542698239a5646c220560
Autor:
Binan Zhao, Haoran Peng, Yanjing Zhang, Jie Zhang, Desheng Kong, Sai Cao, Yan Li, Dan Yang, Chuanwen Sun, Xinyi Pu, Ping Zhao, Yan Xu, Kai Zhao, Liangzhi Xie
Publikováno v:
Biological Research, Vol 57, Iss 1, Pp 1-10 (2024)
Abstract Despite the record speed of developing vaccines and therapeutics against the SARS-CoV-2 virus, it is not a given that such success can be secured in future pandemics. In addition, COVID-19 vaccination and application of therapeutics remain l
Externí odkaz:
https://doaj.org/article/6008b19a32174036ba6c69994551fcc0
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The development of human papillomavirus (HPV) vaccines has made substantive progress, as represented by the approval of five prophylactic vaccines since 2006. Generally, the deployment of prophylactic HPV vaccines is effective in preventing newly acq
Externí odkaz:
https://doaj.org/article/f8fab69ff06a43fa9ad70508ee683905
Autor:
Suad Hannawi, Alaa Abuquta, Linda Saf Eldin, Aala Hassan, Ahmad Alamadi, Cuige Gao, Adam Abdul Hakeem Baidoo, Xinjie Yang, Huo Su, Jinxiu Zhang, Liangzhi Xie
Publikováno v:
Vaccines, Vol 12, Iss 10, p 1109 (2024)
The SARS-CoV-2 evolution trajectory remains uncertain, and the antigenic characteristics of future variants are highly unpredictable. We report the immunogenicity and safety of multivalent COVID-19 vaccines, SCTV01E and SCTV01E-1, against Omicron BA.
Externí odkaz:
https://doaj.org/article/9acce74db117418bb761109905cfd89d
Autor:
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Shuping Xu, Jian Li, Dongfang Liu, Adam Abdul Hakeem Baidoo, Dima Ibrahim, Mojtaba Alhaj, Yuanxin Chen, Qiang Zhou, Liangzhi Xie
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract The safety and immunogenicity of a protein-based tetravalent vaccine SCTV01E that contains spike protein ectodomain (S-ECD) of Alpha, Beta, Delta and Omicron BA.1 are assessed and compared with bivalent protein vaccine SCTV01C (Alpha and Bet
Externí odkaz:
https://doaj.org/article/ff9c0af826f64983a5cc1e23c58c5812
Autor:
Lin Yang, Wen Zhang, Nanfeng Fan, Peiguo Cao, Ying Cheng, Lingjun Zhu, Suxia Luo, Hong Zong, Yuxian Bai, Jianfeng Zhou, Yanhong Deng, Yi Ba, Tianshu Liu, Mayinuer Aili, Xianli Yin, Kangsheng Gu, Guanghai Dai, Jieer Ying, Jianhua Shi, Yajie Gao, Wei Li, Guohua Yu, Liangzhi Xie, Wenlin Gai, Yan Wang, Peng Meng, Yuankai Shi
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104966- (2024)
Summary: Background: Limited therapeutic options are available for metastatic colorectal cancer (mCRC) patients after failure of first- and second-line therapies, representing an unmet medical need for novel therapies. Methods: This is an open-label,
Externí odkaz:
https://doaj.org/article/51a30c01a2774b8782efcb9593d768c2
Autor:
Jing Wu, Guolan Wu, Liangzhi Xie, Duo Lv, Chang Xu, Huili Zhou, Lihua Wu, Jingjing Zhang, Jianzhong Shentu
Publikováno v:
Drugs in R&D, Vol 23, Iss 2, Pp 175-183 (2023)
Abstract Background SCT510 is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), which is intended as a candidate biosimilar of bevacizumab that is approved for various metastatic cancers.Please confirm c
Externí odkaz:
https://doaj.org/article/fd1d35d60c1c4b679c36332c14da4253
Publikováno v:
Vaccines, Vol 12, Iss 6, p 579 (2024)
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the COVID-19 pandemic, has profoundly impacted global healthcare systems and the trajectory of economic advancement. As nations grapple with the far-reach
Externí odkaz:
https://doaj.org/article/5e5679118a1b4ada9e20dd3d1facf57e
Autor:
Suad Hannawi, Lixin Yan, Linda Saifeldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Miaomiao Zhang, Cuige Gao, Yuanxin Chen, Wenlin Gai, Liangzhi Xie
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102195- (2023)
Summary: Background: COVID-19 vaccines that offer broad-spectrum protection are needed. We aimed to evaluate the safety and immunogenicity of multivalent vaccines, SCTV01E and SCTV01C, and compare them with an inactivated vaccine. Methods: In the pha
Externí odkaz:
https://doaj.org/article/5fc2f63fff6240f5bfea16ef564c0589